TICKERNERD
Menu
DFTXHealthcare · Biotechnology

DFTX Stock Forecast: Definium Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$45
−1.08% on the day

The 18 Wall Street analysts covering Definium Therapeutics, Inc. hold a median 12-month price target of $66 — +47.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 40 of 100 as at 22 Aug 2026 — in the lower half.

Market cap
$6.0B
Ticker Nerd rank
40 / 100
Median analyst target
$66
Analysts covering
18
Total return, dividends reinvested
1W
+5.3%
1M
−0.4%
YTD
+235.4%
1Y
+357.3%
From 52W high
−7.3%
From 52W low
+405.7%
$9
$48
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

DFTX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Definium Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
40 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
99
Value
69
Volatility
61
Accruals
59
Quality
47
Issuance
35
Revisions
30
Growth
25
Size
22

Momentum (99): The shares have been drifting up relative to others.

Growth (25): Sales and profits are flat, shrinking, or growing more slowly than they were.

Size (22): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

DFTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on DFTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80$100Oct 25Jan 26Apr 26Jul 26DFTXHigh $90Median $66Low $52

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says18 analysts
18 Buy0 Hold0 Sell
Low $52Median $66High $90

The green dot is the last close — the median target sits +47.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 10 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
18 Aug 2026B of A SecuritiesInitiatesBuy$75
14 Aug 2026Maxim GroupMaintainsBuy$50 → $55
13 Aug 2026BairdMaintainsOutperform$57 → $75
13 Aug 2026Canaccord GenuityMaintainsBuy$58 → $64
13 Aug 2026Jones TradingMaintainsBuy$74 → $90
13 Aug 2026RBC CapitalMaintainsOutperform$57 → $66
13 Aug 2026Wells FargoMaintainsOverweight$68 → $72
12 Aug 2026NeedhamMaintainsBuy$50 → $66
7 Aug 2026Piper SandlerReiteratesOverweight—
7 Aug 2026Piper SandlerReiteratesOverweight$73 → $75
27 July 2026Wells FargoInitiatesOverweight$68
27 July 2026Wells FargoInitiatesOverweight—
24 July 2026Piper SandlerReiteratesOverweight—
24 July 2026Piper SandlerReiteratesOverweight$48 → $73
8 July 2026StifelMaintainsBuy—
8 July 2026StifelMaintainsBuy$30 → $60
30 June 2026Canaccord GenuityMaintainsBuy—
24 June 2026Jones TradingMaintainsBuy—
23 June 2026BairdMaintainsOutperform—
23 June 2026NeedhamMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DFTX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

DFTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

Definium Therapeutics, Inc. (DFTX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−21.8×

Cheaper than 96% of US stocks

Price / sales
—
Price / book
6.6×

Cheaper than 16% of US stocks

EV / EBITDA
−32.1×

Cheaper than 91% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−64.1%

Higher than 18% of US stocks

Return on assets
−20.6%

Higher than 19% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

DFTX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
DFTXDefinium Therapeutics, Inc.$6.0B
40
XENEXenon Pharmaceuticals, Inc.$5.8B
49
PTCTPTC Therapeutics, Inc.$5.8B
67
CRSPCRISPR Therapeutics AG$5.7B
31
LGNDLigand Pharmaceuticals, Inc.$5.6B
73
ERASErasca, Inc.$6.0B
55
DNTHDianthus Therapeutics, Inc.$6.0B
60

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Definium Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest DFTX news & analysis

This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Benzinga · 18 Aug 2026positive

Benzinga reported that a Wall Street analyst began coverage on Definium Therapeutics on a bullish note, listing the initiation among the top five analyst rating changes for Tuesday. The article also directs readers to a full analyst-ratings page for all upgrades, downgrades, and initiations.

Why it matters — A analyst initiation with a bullish stance on Definium Therapeutics indicates increased Wall Street attention and a fresh assessment of the company.

Definium Therapeutics Announces New Employee Inducement Grants

Business Wire · 17 Aug 2026neutral

Definium Therapeutics announced the issuance of inducement grants to two newly hired non-executive employees, consisting of options to purchase an aggregate of 32,900 common shares with effective grant dates of August 17, 2026.

Why it matters — A DFTX watcher would care because the equity inducement grants signal new hiring and potential dilution of common shares.

Definium Therapeutics' DT120 Meets Phase III Goals in GAD Study

MarketBeat · 13 Aug 2026positive

Definium Therapeutics reported positive top-line results from Voyage, its Phase III study of a single 100 mcg dose of DT120 ODT for generalized anxiety disorder. The trial met its primary endpoint and all key secondary endpoints, showing rapid and durable improvements in anxiety symptoms through 12 weeks.

Why it matters — The Phase III success for DT120 represents a significant clinical milestone for Definium and its lead candidate in the GAD indication.

Definium Therapeutics, Inc. (DFTX) Discusses Phase 3 Voyage Study Topline Results for DT120 in Generalized Anxiety Disorder Transcript

Seeking Alpha · 12 Aug 2026neutral

Definium Therapeutics (DFTX) discussed topline results from the Phase 3 Voyage Study evaluating DT120 for generalized anxiety disorder during a transcript event covered by Seeking Alpha.

Why it matters — Phase 3 data for DT120 is a key clinical milestone for DFTX, and the discussion provides investors with direct insight into the trial outcomes and potential path forward for the drug candidate.

Definium Therapeutics: 'Strong Buy' On Positive DT120 ODT Data, Two Indications, And September 2026 Catalyst

Seeking Alpha · 12 Aug 2026positive

Definium Therapeutics received a 'Strong Buy' rating following positive phase 3 VOYAGE data for DT120 ODT in generalized anxiety disorder, with a statistically significant -5.4 placebo-adjusted reduction in HAM-A score at 12 weeks. Upcoming catalysts include phase 3 PANORAMA GAD data in September 2026 and ASCEND MDD topline results in 2027.

Why it matters — DFTX watchers would care because the positive phase 3 data and scheduled 2026-2027 catalyst readouts signal progress across two indications for DT120 ODT.

FAQ

Frequently asked questions about DFTX stock

What is the DFTX stock price forecast for 2026-2027?

The 18 Wall Street analysts covering Definium Therapeutics, Inc. have a median 12-month price target of $66, with estimates ranging from $52 to $90. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is DFTX stock a buy right now?

Of the 18 analysts covering Definium Therapeutics, Inc., 18 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Definium Therapeutics, Inc. 40 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank DFTX?

As at 22 Aug 2026, Definium Therapeutics, Inc. ranks 40 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (99 of 100).

Will DFTX stock go up?

No one can know that. What the data says: the median 12-month target from 18 analysts implies +47.0% from the last close, and Ticker Nerd's factor model ranks Definium Therapeutics, Inc. 40 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the DFTX stock forecast for 2030?

No analyst covering Definium Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DFTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $52 to $90 over the next 12 months.

How has DFTX stock performed over the past year?

Definium Therapeutics, Inc. returned +357.3% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Definium Therapeutics, Inc. do?

Definium Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for psychiatric and neurological disorders.

What is the latest news on DFTX?

The most recent item we track (Benzinga, 18 Aug 2026): "This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday". Benzinga reported that a Wall Street analyst began coverage on Definium Therapeutics on a bullish note, listing the initiation among the top five analyst rating changes for Tuesday. The article also directs readers to a full analyst-ratings page for all upgrades, downgrades, and initiations.

Company

About Definium Therapeutics, Inc.

Definium Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for psychiatric and neurological disorders. Headquartered in New York City, the company applies scientific rigor to psychedelic-based medicine to address underlying disease mechanisms rather than temporary symptom relief. Definium’s lead program centers on DT120, an orally disintegrating tablet formulation of lysergide (LSD) being evaluated in late-stage clinical trials for major depressive disorder and generalized anxiety disorder, where it has received FDA Breakthrough Therapy Designation for GAD. The company is also advancing DT402, the R-enantiomer of MDMA, targeting core symptoms of autism spectrum disorder, particularly social communication challenges. Operating within the pharmaceuticals and biotechnology sectors, Definium Therapeutics occupies a specialized position in the emerging field of evidence-based psychedelic therapeutics, aiming to provide accessible, scalable treatment options across high-burden mental health and brain health indications.

CEO Mr. Robert Barrow · 105 employees · United States · https://definiumtx.com